Kwality Pharmaceuticals is currently trading at Rs. 415.00, up by 9.90 points or 2.44% from its previous closing of Rs. 405.10 on the BSE.
The scrip opened at Rs. 409.00 and has touched a high and low of Rs. 445.60 and Rs. 381.55 respectively. So far 97936 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 961.50 on 03-Jan-2022 and a 52 week low of Rs. 265.60 on 08-Aug-2022.
Last one week high and low of the scrip stood at Rs. 445.60 and Rs. 355.00 respectively. The current market cap of the company is Rs. 429.52 crore.
The promoters holding in the company stood at 54.45% while Non-Institutions held 45.55% stake in the company.
Kwality Pharmaceuticals has received approval from Brazil's National Health Surveillance Agency ANVISA (Agencia Nacional de Vigilancia Sanitaria) for its Injectable formulations manufacturing unit at Amritsar along with Oncology Injectable unit at Himachal Pradesh.
The approval grants access to the Company to register and market its products at the large and growing Brazilian Pharmaceutical Market. The ANVISA approved facility is capable to manufacture liquid injection (in form of Ampoule and vials) and lyophilized formulation (vials).
Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company. It is engaged in manufacturing finished pharmaceutical formulations in dosage form.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.95 |
| Dr. Reddys Lab | 1242.75 |
| Cipla | 1230.00 |
| Zydus Lifesciences | 935.00 |
| Lupin | 2337.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: